No Data
RBC Capital Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $24
Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $31
Apellis Pharmaceuticals Analyst Ratings
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Raises Target Price to $31
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes